Calculation of operating expenses for conventional Transarterial Chemoembolization in an academic medical center: A step toward defining the value of Transarterial Chemoembolization

Journal of Vascular and Interventional Radiology

Volumn 25, Issue 4, 2014, Pages 567-574

  Beheshti, Michael V ^a,b   Meek, James ^a  

^a UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

^b CENTRAL ARKANSAS VETERANS HEALTHCARE SYSTEM   (United States)

Author keywords

Abbreviation; HCC; hepatocellular carcinoma

Indexed keywords

DOXORUBICIN; ETHIODIZED OIL; MITOMYCIN; CEFTRIAXONE; DEXAMETHASONE; FENOLDOPAM; FENTANYL; GELATIN SPONGE; HYDROMORPHONE; IODINATED POPPYSEED OIL; IODIXANOL; KETOROLAC; MIDAZOLAM; ONDANSETRON; PETHIDINE; PROMETHAZINE;

ACCOUNTING; ANGIOGRAPHY; ARTICLE; CANCER PATIENT; CHEMOEMBOLIZATION; COMPENSATION; CONTRACT; COST BENEFIT ANALYSIS; HOSPITAL CHARGE; HOSPITALIZATION COST; HUMAN; INTRAHEPATIC DRUG ADMINISTRATION; LIVER CELL CARCINOMA; NURSING ASSISTANT; OUTPATIENT CARE; PRIORITY JOURNAL; REFERENCE VALUE; RETROSPECTIVE STUDY; WORKLOAD; CLINICAL ARTICLE; DRUG COST; EMBOLIZATION COIL; HEALTH CARE COST; INFUSION SYSTEM; INOPERABLE CANCER; MICROCATHETER; NASAL CANNULA; OUTPATIENT; SUTURE; SYRINGE; UNIVERSITY HOSPITAL; VASCULAR CLOSURE DEVICE; VASCULAR GUIDE WIRE; AMBULATORY CARE; CARCINOMA, HEPATOCELLULAR; DISPOSABLE EQUIPMENT; ECONOMICS; HOSPITAL COST; HOSPITAL PERSONNEL; INTERVENTIONAL RADIOLOGY; LIVER NEOPLASMS; RADIOGRAPHY; SALARY AND FRINGE BENEFIT; TIME; TREATMENT OUTCOME; UNITED STATES;

ACADEMIC MEDICAL CENTERS; AMBULATORY CARE; ARKANSAS; CARCINOMA, HEPATOCELLULAR; CHEMOEMBOLIZATION, THERAPEUTIC; COST-BENEFIT ANALYSIS; DIRECT SERVICE COSTS; DISPOSABLE EQUIPMENT; DRUG COSTS; HOSPITAL COSTS; HUMANS; LIVER NEOPLASMS; PERSONNEL, HOSPITAL; RADIOGRAPHY, INTERVENTIONAL; RETROSPECTIVE STUDIES; SALARIES AND FRINGE BENEFITS; TIME FACTORS; TREATMENT OUTCOME;

EID: 84897115399     PISSN: 10510443     EISSN: 15357732     Source Type: Journal    
DOI: 10.1016/j.jvir.2013.10.023     Document Type: Article

References (27)

1. M.E. Porter, and E.A. Teisberg Redefining Health Care: Creating Value-Based Competition on Results 2006 Harvard Business School Press Boston
2. M.E. Porter A strategy for health care reform - toward a value-based system N Engl J Med 361 2009 109 112
3. M.E. Porter What is value in health care? N Engl J Med 363 2010 2477 2481
4. C.M. Christensen, J.H. Grossman, and J. Hwang The Innovator's Prescription. A Disruptive Solution for Health Care 2009 McGraw Hill New York
5. M.R. Gold, J.E. Siegel, L.B. Russell, and M.C. Weinstein Cost-effectiveness in Health and Medicine 1996 Oxford University Press New York
6. R. Whitney, V. Valek, and J.F. Fages et al. Transarterial chemoembolization and selective internal radiation for the treatment of patients with metastatic neuroendocrine tumors: a comparison of efficacy and cost Oncologist 16 2011 594 601
7. M.G. Hunink, K.A. Cullen, and M.C. Donaldson Hospital costs of revascularization procedures for femoropopliteal arterial disease J Vasc Surg 19 1994 632 641
8. J.S. Schwartz Clinical economics and noncoronary vascular disease J Vasc Interv Radiol 6 suppl 1995 116S 124S
9. D. Picus Comparing competing medical procedures: costs or charges - what should it matter? Radiology 199 1996 623 624
10. S. Brill Bitter pill: why medical bills are killing us Time 2013 1 30
11. J.M. Llovet, M.I. Real, and X. Monttana et al. Arterial embolization or chemoembolization versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomized controlled trial Lancet 359 2002 1734 1739
12. C.M. Lo, W.K. Ngan, and C.L. Liu et al. Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma Hepatology 35 2002 1164 1171
13. G. Cabibbo, M. Enea, M. Attanasio, J. Bruix, A. Craxi, and C. Camma A meta-analysis of survival rates of untreated patients in randomized clinical trials of hepatocellular carcinoma Hepatology 51 2010 1274 1283
14. R. Salem, R.J. Lewandowski, and M.F. Mulchahy et al. Radioembolization of hepatocellular carcinoma using yttrium-90 microspheres: a comprehensive report of long-term outcomes Gastroenterology 138 2010 52 64
15. R. Salem, R.J. Lewandowski, and L. Kulik et al. Radioembolization results in longer time-to-progression and reduced toxicity compared with chemoembolization in patients with hepatocellular carcinoma Gastroenterology 140 2011 497 507
16. S.V. Williams, S.A. Finkler, and C.M. Murphy et al. Improved cost allocation in case-mix accounting Med Care 20 1982 450 459
17. R.R. Roberts, P.W. Frutos, and G.G. Ciavarella et al. Distribution of variable vs. fixed costs of hospital care JAMA 281 1999 644 649
18. B.J. d'Othée, D.R. Langdon, G.K. Bell, and M.A. Bettmann Operating expenses for the diagnosis and treatment of peripheral vascular disease in an academic interventional radiology department: cost calculations according to a microeconomic method J Vasc Interv Radiol 17 2006 85 94
19. M.C. Weinstein, J.E. Siegel, and M.R. Gold et al. Recommendations of the Panel on Cost-effectiveness in Health and Medicine JAMA 276 1996 1253 1258
20. B.J. Hillman Outcomes research and cost-effectiveness analysis for diagnostic imaging Radiology 193 1994 307 310
21. M.G. Hunink Outcomes research and cost-effectiveness analysis in radiology Eur Radiol 6 1996 615 620
22. Hunink MG, Glasziou PP, Siegel JE, et al. Decision Making in Health and Medicine. Integrating Evidence and Values. New York: Cambridge University Press; 2009:245-271
23. C.E. Ray Jr, C. Battaglia, A.M. Libby, A. Prochazka, S. Xu, and B. Funaki Interventional radiologic treatment of hepatocellular carcinoma - a cost analysis from the payer perspective J Vasc Interv Radiol 23 2012 306 314
24. N. Kothary, J.L. Weintraub, J. Susman, and J.H. Rundback Transarterial chemoembolization for primary hepatocellular carcinoma in patients at high risk J Vasc Interv Radiol 18 2007 1517 1526
25. Y.C. Cheung, S.F. Ko, S.H. Ng, S.C. Chan, and Y.F. Cheng Survival outcome of lobar or segmental transcatheter arterial embolization with ethanol-lipiodol mixture in treating hepatocellular carcinoma World J Gastroenterol 11 2005 2792 2795
26. J.W. Mitchell, W.G. O'Connell, and P. Kisza et al. Safety and feasibility of outpatient transcatheter hepatic arterial embolization for hepatocellular carcinoma J Vasc Interv Radiol 20 2009 203 208
27. H.J. Prajapati, S. Rafi, B.F. El-Rayes, J.S. Kauh, D.A. Kooby, and H.S. Kim Safety and feasibility of same-day discharge of patients with unresectable hepatocellular carcinoma treated with doxorubicin drug-eluting bead transcatheter chemoembolization J Vasc Interv Radiol 23 2012 1286 1293